🔎︎
Cardiovascular disease caused 916,000 deaths in 2023, maintaining its position as the leading U.S. killer despite improved therapies, according to American Heart Association statistics reported in The New York Times. The findings highlight substantial opportunities for managed care interventions in screening, disease management, and care optimization.
Heart disease and stroke together account for more than one quarter of all U.S. deaths, exceeding cancer and accidental injuries combined. While 2023 mortality figures represent improvement from pandemic-era peaks, they underscore persistent gaps between available treatments and population health outcomes.
Disease control represents a significant challenge for payers and providers. Nearly half of U.S. adults have hypertension, yet fewer than 25 percent achieve adequate control through lifestyle modifications or pharmacotherapy. Uncontrolled blood pressure contributes to heart failure, arterial disease, heart attack, and stroke.
Diabetes affects approximately 14 percent of adults, with 10 million cases undiagnosed. Additionally, 37 percent of adults have prediabetes. Less than half of diagnosed patients maintain adequate glycemic control, contributing to vascular damage and cardiovascular complications, including heart attack, stroke, and kidney disease.
Dr. Sadiya Khan, vice-chair of the report committee at Northwestern University, identified screening and patient education as key areas for improvement. Enhanced identification of diabetes and kidney disease, combined with preventive education, could reduce cardiovascular risk across covered populations.
The report examined care-delivery patterns and identified gaps in the utilization of evidence-based interventions. Cardiac rehabilitation participation remains low among eligible heart failure patients despite demonstrated quality of life benefits, suggesting opportunities for improved care coordination and member engagement.
The obesity epidemic continues to drive cardiovascular risk factors. Approximately 11 percent of adults smoke cigarettes, while e-cigarette use increases among adults. New therapeutic options for obesity, diabetes, cholesterol, and heart failure offer potential for improved outcomes, though systematic implementation remains challenging.
Addressing cardiovascular mortality requires coordinated approaches spanning screening programs, disease management initiatives, medication optimization, and care coordination to close gaps between clinical capabilities and population outcomes.
